Myocardial infarction, persistent coronary artery thrombosis and lupus anticoagulant

Mills, Tillet J.; Safford, Robert E.; Kazmier, Francis J.

doi:10.1016/0167-5273(88)90224-0

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, a case-control study of urban and rural populations in Tanzania showed a strong association between LAC and stroke especially in young and middle-aged individuals [94]. Several case reports indicated that LAC positivity should be sought in arterial thrombosis, especially in young adults, and treated to prevent recurrence [95][96][97][98].…”

Section: Lac and Arterial Thrombosismentioning

confidence: 99%

VWF, Platelets and the Antiphospholipid Syndrome

Huang

Ninivaggi

Chayouâ

et al. 2021

IJMS

View full text Add to dashboard Cite

The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). Laboratory criteria for the classification of APS include the detection of lupus anticoagulant (LAC), anti-cardiolipin (aCL) antibodies and anti-β2glycoprotein I (aβ2GPI) antibodies. Clinical criteria for the classification of thrombotic APS include venous and arterial thrombosis, along with microvascular thrombosis. Several aPLs, including LAC, aβ2GPI and anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have been associated with arterial thrombosis. The Von Willebrand Factor (VWF) plays an important role in arterial thrombosis by mediating platelet adhesion and aggregation. Studies have shown that aPLs antibodies present in APS patients are able to increase the risk of arterial thrombosis by upregulating the plasma levels of active VWF and by promoting platelet activation. Inflammatory reactions induced by APS may also provide a suitable condition for arterial thrombosis, mostly ischemic stroke and myocardial infarction. The presence of other cardiovascular risk factors can enhance the effect of aPLs and increase the risk for thrombosis even more. These factors should therefore be taken into account when investigating APS-related arterial thrombosis. Nevertheless, the exact mechanism by which aPLs can cause thrombosis remains to be elucidated.

show abstract